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Abstract
Background:  Prostate cancer is a major cause of cancer-related 
death in men. Therefore there has been considerable interest to 
explore neoadjuvant therapy. Polypeptide extracted from scorpion 
venom (PESV), originally obtained from the East-Asian scorpion 
Buthus martensi Karsch (BmK), is being studied for both preven-
tion and treatment of various human malignancies including pros-
tate cancer.
Methods:  The present study was to investigate the effect of PESV 
on cell proliferation, cell cycle, and apoptosis in human androgen-
independent prostate cancer cells DU-145 in vitro.
Results:  PESV treatment on these cells resulted in a significantly 
dose-dependent growth inhibition with a G1 phase arrest at 40 µg/
mL after 48h treatment. PESV treatment strongly induced expres-
sion of p27 (Kip1), but resulted in a decrease in cyclin E, one of 
cyclins involved in G1 progression.  In other studies, PESV treat-
ment also induced high apoptosis index (AI), confirmed by TdT-
mediated dUTP-biotin nick-end labeling (TUNEL) assay. Further, 
the apoptosis induction by PESV (40µg/mL) in DU145 cells was 
associated with an increase of pro-apoptotic protein Bax.
Conclusions:  These results suggest that PESV modulates the ex-
pression of cell cycle-related and apoptosis-related proteins and 
induces growth inhibition and apoptosis of DU145 cells, provid-
ing a strong rationale for future studies to evaluate prevention or/
and intervention strategies for PESV in pre-clinical prostate cancer 
models.
Keywords:  Prostate cancer, PESV, cell proliferation, cell cycle, 
apoptosis
Introduction
Prostate cancer (PCa) is the most invasive and frequently 
diagnosed malignancy in males in the USA and, at present, 
is the second leading cause of cancer deaths in North Ameri-
can men [1]. The induction of human PCa has been viewed 
as a multistage process, involving progression from small, 
latent carcinomas of low histological grade to large, metas-
tasis carcinomas of higher grade [2–4]. Since the growth and 
development of PCa is initially androgen-dependent, there-
fore androgen deprivation has been extensively explored as a 
strategy for PCa prevention and treatment [4, 5]. While PCa 
patients treated with androgen-deprivation therapy often have 
remission within a few years, tumor regrowth occurs, which 
is largely due to the progression of initially androgen depen-
dent PCa cells to tumor cells that do not depend on androgen 
for their proliferation [6, 7]. At this stage of the disease, the 
uncontrolled growth and metastasis potential of malignant 
cells are extremely aggressive, and unfortunately, the prog-
nosis is death of the patient [6–8]. Hormone refractory pros-
tate cancer (HRPC) remains a challenge in the management 
of prostate cancer patients. Hence, it would be important to 
find promising agents against advanced androgen-indepen-
dent prostate cancer. Chinese medicine which contains many 
chemical compounds exhibited anti-proliferative effects on 
cancer cells [9].  Medicinal herbs with anticancer activity 
have long been used for the treatment or prevention of vari-
ous human disorders in folk medicine [10-14]. 
Buthus martensi Karsch (BmK), a species belonging to 
the Buthidae family, extensively distributed from northwest-
ern China to Mongolia and Korea, is a Chinese herb used for 
the treatment of various abdominal masses in folk medicine. 
Polypeptide extract from scorpion venom (PESV), a certain 
group of polypeptide of 50-60 amino acids extracted from 
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Crude venom of BmK with bioactivities, has been reported 
to  have  anti-tumor  activity.  Our  previous  results  showed 
that PESV exhibited potent anti-proliferative and apoptosis-
induced activity against HUVEC, inhibition of neovascular-
ization, suppression of tumor growth of S180 sarcoma and 
H22 hepatocelluar carcinoma in mice [15,16]. In the present 
study, we tried to look at the effect of PESV on cell prolifera-
tion, apoptosis, as well as cell cycle in prostate cancer cells, 
and further study the possibility of PESV as a potent agent 
in prevention and/or intervention of human prostate cancer.
Several recent studies by others and us have demon-
strated that the cancer preventive and therapeutic efficacy 
of scorpion venom in different animal tumor models and 
cell  culture  systems  including  prostate,  breast,  colon  and 
skin cancers [17-23]. Recent studies have begun to eluci-
date the underlying genetic determinants of the morphologic 
and biologic characteristics of prostate cancer [24-26]. The 
molecular and genetic alterations that precede morphologi-
cal changes and are responsible for tumorigenesis and pro-
gression of prostate cancer also include alterations in cell 
cycle regulators and apoptosis-related proteins causing un-
controlled cancer growth. In general, the progression of cell 
cycle in eukaryotes is a complex process involving arresting 
G0 phase, and cell growth involving G1, S and G2/M phases 
in a step-wise manner [27]. These cell cycle phases receive 
different growth controlling signals that are integrated and 
processed for the sequential activation of different members 
of the cyclin-dependent kinases (CDKs), which are serine/
threonine kinases [27-30]. Different CDKs govern different 
phases of the cell cycle such as G1 by CDK4/CDK6, late G1 
to early S by CDK2, and G2/M by p34Cdc2 (CDK1) kinase 
[27-30]. The kinase activity of CDKs is governed by their 
regulatory subunits known as cyclins, which form a com-
plex with their catalytic subunit CDKs and are activated at 
a specific phase of the cell cycle [31-33]. The other impor-
tant components that control CDK kinase activity are cyclin-
dependent kinase inhibitors (CDKIs) Cip1/p21 and Kip1/
p27 [31-33]. CDKI is shown to inhibit the kinase activity of 
CDK–cyclin complexes and thus modulates retinoblastoma 
(Rb) phosphorylation events, which are essential for various 
cell cycle transitions [31, 34, 35]. 
Apoptosis is regulated by several protein families, in-
cluding the upstream Bcl-2 family (e.g., the anti-apoptotic 
Bcl-2 and pro-apoptotic Bax) and the downstream caspase 
family (e.g., caspase-3). The activation of apoptosis is con-
trolled at multiple checkpoints within the cell. Upstream, the 
pro-apoptotic Bax and anti-apoptotic Bcl-2 are membrane-
bound pore-forming proteins that interact through heterodi-
merization. Together they regulate the mitochondrial trans-
membrane passage of cytochrome c, which in turn activates 
caspase proteins. The Bax/Bcl-2 ratio appears more impor-
tant than the individual Bax or Bcl-2 level in determining a 
cell’s vulnerability to apoptosis; high Bax/Bcl-2 ratios lead 
to greater apoptotic activity [36].
Materials and Methods
Cell culture and treatment
DU145 cells, derived from a brain metastasis of a pros-
tate  cancer  patient,  were  purchased  from  the  Institute  of 
Pharmacy, Chinese Academy of Medical Sciences (Beijing, 
China) and maintained in medium RPMI 1640 supplemented 
with 10% fetus bovine serum (FBS) in a humidified atmo-
sphere of 5% CO2 at 37°C. Cells were harvested when they 
were approximately 70% - 80% confluent. Cells were treated 
with serial concentrations of PESV in the following experi-
ments. Untreated cells were used as controls. 
Cytotoxicity test of PESV using MTT colorimetric assay
The effect of PESV on the viability of DU145 cells was 
determined  by  3-(4,  5-dimethylthiazol-2-yl)-2,  5-diphenyl 
tetrazolium bromide (MTT) assay. The cells were plated at 
2x105 cells per well in 200 µL RPMI 1640 containing 0, 10, 
20, 40, 80, 100, and 200 mg/mL PESV in a 96-well microtiter 
plate. Each concentration of PESV was repeated in 10 wells. 
The cells were incubated for 48 hours at 37°C in an incuba-
tor. Following 24 hours of incubation, MTT reagent (4 µL, 
5 mg/mL in PBS) was added to each well and incubated for 
2 hours. The microtiter plate containing the cells was centri-
fuged at 1,800 rpm for 5 minutes at 4°C. The MTT solution 
was removed from the wells by aspiration and the formazan 
crystals were dissolved in DMSO (150 µL). Absorbance was 
recorded on a microplate reader at 540 nm wavelength.
Detection of apoptosis by TUNEL assay
Coverslips  with  adherent  cells  treated  with  PESV 
(40mg/mL) for 48 hours were fixed in 4% paraformaldehyde 
for 15 minutes at room temperature. Then rinsed in distilled 
water and incubated with 0.2% Triton X-100 in phosphate 
buffered  saline  solution  (PBS)-Tween  20  for  30  minutes. 
DNA fragments were labeled with TUNEL-Enzyme (Boeh-
ringer Mannheim). The kit was used according to the man-
ufacturer’s instructions, with the addition of incubation in 
TdT Reaction Buffer for 10 minutes before TUNEL reaction. 
The coverslips were then incubated in TdT Reaction Mix-
ture for 2 hours at 40-45 °C in humidified chamber, rinsed 
in stop wash buffer for 10 minutes and PBS-Tween 20 for 
3 x 2 min. The reaction was detected by incubating cover-
slips with Streptavidin-HRP in PBS for 20 minutes at room 
temperature. Then rinse in PBS-Tween 20 for 3 x 2 min, and 
incubate sections with DAB solution for 5-10 minutes. Cells 
were counterstained with hematoxylin.
Assessment of the apoptotic index
A Positive signal was defined as the presence of a dark 
brown staining on nuclei of the neoplastic cells or on apop-
totic bodies as morphologically defined. Cells were defined 
as apoptotic if the whole nuclear area of cells labeled posi-
tively. Apoptotic bodies were defined as small, positively 
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labeled, globular bodies in the cytoplasm of the tumor cells 
that could be found either singly or in groups. The apoptotic 
index was determined by the percentage of apoptotic cells 
divided by the number of tumor cells in 400x magnifica-
tion. A total of at least 1000 neoplastic nuclei were counted 
based on 10 randomly chosen fields at 400x magnification 
[37]. Apoptotic cells were identified by TUNEL in conjunc-
tion with characteristic morphological changes, such as cell 
shrinkage, membrane blebbing, and chromatin condensation.
DNA cell cycle analysis
The  DU145  cells  treated  with  PESV  (40  mg/mL)  in 
complete medium for 48 hours. The cells were trypsinized 
thereafter, washed twice with cold PBS, and centrifuged. 
The cell pellet was resuspended in 50 µL cold PBS to which 
cold methanol (450 µL) was added and the cells were incu-
bated for 1 hour at 4°C. The cells were centrifuged at 1,100 
rpm for 5 minutes, washed twice with cold PBS, suspended 
in 500 µL PBS, and incubated with 5 µL RNase (20 µg/mL 
final concentration) for 30 minutes. The cells were chilled 
over ice for 10 minutes and incubated with propidium iodide 
(50 µg/mL final concentration) for an additional 30 min in 
the dark. Cells were then analysed for DNA content using 
a Becton-Dickinson flow cytometor to determine cell cycle 
phase.
Immunohistochemical stainings
Coverslips with adherent cells treated with PESV (40mg/
mL) for 48 hours were fixed in 4% paraformaldehyde for 15 
minutes at room temperature. DU145 cells were subjected 
to  immunohistochemical  staining,  with  standard  streptav-
idinbiotin-  peroxidase  techniques,  with  diaminobenzidine 
as the chromogen. In brief, DU145 cells were quenched for 
10 minutes with 3% hydrogen peroxide, preincubated with 
blocking serum at 1:20 in 2% bovine serum albumin (BSA)/
PBS for 15 minutes at room temperature. After incubation 
with the primary antibodies, slides were rinsed with PBS, 
and the secondary antibody was applied at 1:500 in PBS for 
30 minutes at room temperature. After rinses with PBS for 
30 seconds, slides were incubated with streptavidin/peroxi-
dase at 1:500 in PBS for 30 minutes at room temperature, 
then rinsed with PBS and incubated for 15 minutes in 0.06% 
diaminobenzidine  and  counter-stained  with  hematoxylin. 
The following antibodies were used for immunohistochemi-
cal staining: Bcl-2 (clone: 124,1:40 dilution, incubation for 2 
hours; Dako Corp, Carpinteria, CA), Bax (clone: H62, 1:100 
dilution, incubation overnight; Santa Cruz Biotechnology, 
Inc, Santa Cruz, CA), P27/kip1(clone:M197,1:100 dilution, 
incubation overnight; Santa Cruz Biotechnology, Inc, Santa 
Cruz, CA  ), Cyclin E (clone:M-20,1:50 dilution, incubation 
overnight; Santa Cruz Biotechnology, Inc, Santa Cruz, CA 
). Replacing the primary antibody by PBS/5%BSA included 
negative controls.
Assessment of protein immunoreactivity by Leica QWin 
V3 software
Immunoreactivity  was  quantified  within  5  random 
fields at 100x magnification with a Leica DM4000 B sys-
tem and Leica QWin V3 software was applied to evaluate 
grey scale intensity variations. In computing, a grayscale 
or greyscale digital image is an image in which the value 
of each pixel is a single sample. Displayed images of this 
sort are typically composed of shades of gray, varying from 
black at the weakest intensity to white at the strongest. The 
grey scale intensity and protein expression have inverse re-
lation.
Statistics assay
All data are expressed as the mean ± SE. A t test for 
unpaired or paired data, as appropriate, was used to compare 
continuous variables between groups. P < 0.05 was consid-
ered to indicate statistical significance. All calculations were 
performed using the SPSS 10.0 statistical package.
 
Results
Inhibition of Cell Proliferation of DU145 cells
We evaluated whether PESV treatment imparts antipro-
liferative effects in human prostate cancer cells. Employing 
the MTT assay, we observed that PESV (10- 200 mg/L) treat-
ment on DU145 cells resulted in dose-dependent decrease in 
the cell growth (Fig. 1).
Induction of cell apoptosis of DU145 cells and apoptosis 
index
DU145 cells after exposure to PESV were stained by 
TUNEL. As shown in Fig. 2, apoptotic nuclei and fragment-
ed DNA were stained dark brown in treated cells (Fig. 2b) 
but not in the untreated controls (Fig. 2a). The apoptotic in-
dex is significantly higher in the PESV-treated cells than in 
the control (Table 1).
Apoptosis-related protein expression
Grey Scale Intensity variants of Bax and Bcl-2 immu-
Table 1. Effect of PESV on apoptosis in prostate cancer 
cells DU145 (TUNEL Assay)
Treatment Apoptosis index (%)
 
P value 
Control 
 
3.6 ± 0.02
 
PESV (40 mg/L) 
 
8.3 ± 0.04  0.001
26                                                                                                                                                                                               27J Clin Med Res  •  2009;1(1):24-31 Zhang et al
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
noreactivity were evaluated by Leica QWin V3 software in 
DU145 cells treated with PESV and control group. Fig. 3 in-
dicated the inverse relation between the grey scale intensity 
and protein expression. Higher grey scale intensity stands 
for weaker protein expression, and lower intensity stands for 
stronger protein expression. Treatment with PESV resulted 
in overexpression of Bax in DU145 cells, whereas Bcl-2 ex-
pression reduced. In each comparison, there was a significant 
difference (P < 0.05).
Cell cycle analysis and cell cycle-related protein expres-
sion
We determined the cell cycle phenotype of DU145 cell 
line by flow cytometry. As shown in Figure 4, DU145 cells 
exhibited PESV-associated G1/S arrest occurring at 48 h after 
exposure to PESV (40 mg/mL). Cells showed a lack of pro-
liferation at 48 h in comparison with untreated controls (not 
shown), indicating that the PESV (40 mg/mL) caused prolif-
eration arrest. We further detected the expression of cycle-
related protein cyclin E and p27 by immunohistochemical 
staining. Immunoreactivity was quantified within 5 random 
fields at 100x magnification. As shown in Fig. 5 and Fig. 6, 
cyclin E and p27(Kip1) immunostaining pattern was nuclear. 
DU145 cells exhibited lower expression of cyclin E protein 
and higher expression of p27(Kip1) protein after exposure to 
PESV (40 mg/mL) compared with untreated control.
Discussion
  
The present study investigates the biological effects of 
PESV,  the  major  biologically  active  component  in  crude 
scorpin venom, on human prostate cancer DU145 cells. The 
data support the hypothesis that PESV could be an effective 
chemoprevention/intervention agent for prostate cancer. Our 
results clearly demonstrate that PESV induces cell cycle ar-
rest and growth inhibition in human prostate cancer cells, 
and it induces cell apoptosis at 40 mg/mL concentration with 
apoptosis index (AI) higher than the controls.
The molecular studies reported here demonstrate that 
PESV strongly induces the protein expression of Kip1/p27, 
and decreases cyclin E expression, with an increased inter-
Figure 1. Effect of PESV on the growth of prostate cancer cells 
DU145. Cells were treated with PESV (10, 20, 40, 80, 100, and 
200mg/L), and the percentage inhibition of cell growth was deter-
mined by MTT assay in a 96-well microtiter plate as detailed in Ma-
terials and Methods. Columns, mean of three separate experiments 
wherein each treatment was repeated in 10 wells; bars, SE.
Figure 2. Detection of PESV-induced apoptosis on DU145 cells by 
DNA  fragment  TUNEL  staining. Apoptotic  nuclei  and  fragmented 
DNA were stained dark brown in treated cells (2b) but not in untreat-
ed controls (2a) in DU145 cells. Original magnification x400.
Figure 3. Grey Scale Intensity variants evaluated by Leica QWin V3 
software of Bax and Bcl-2 immunoreactivity in DU145 cells treated 
with PESV and control group. Higher grey scale intensity standing 
for weaker protein expression,and lower ,sronger protein expression. 
Columns, mean of three separate experiments conducted in triplicate 
with DU145 cells; bars, SE.
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action/binding  between  CDKIs  and  CDK  which  possibly 
causes an inhibition in the kinase activity of CDKs. These 
mechanistic observations were in accordance with an overall 
efficacy of PESV in inducing a G1 arrest in the cell cycle 
followed by the inhibition of cell growth.
Cell division depends on the activation of cyclin, which 
binds to CDKs to induce cell cycle progression towards S 
phase and later to initiate mitosis; uncontrolled CDK kinase 
activity is one of the major causes of cancer progression as 
their functions are tightly regulated by CDKIs such as the 
Cip1/p21 and Kip1/p27 proteins in normal cell cycle pro-
gression  [38].  Following  anti-mitogenic  signals  or  DNA 
damage, CDKIs (Cip1/p21 and Kip1/p27) bind to the cy-
clin–CDK complexes to inhibit their catalytic activity and 
thus  inhibit  cell  cycle  progression  [38].  The  Rb  protein, 
which is involved in the regulation of the transcription factor 
E2F [41], is a critical determinant for the restriction-point 
transition during G1 phase [38, 39], as it is phosphorylated 
during G1 phase initially by CDK4 or CDK6 and is subse-
quently maintained in this form by CDK2 [40, 41]. 
The expression level of cyclins is also an important de-
terminant in cell cycle progression particularly during G1/S 
and G2/M transitions [38]. D-type cyclins have been shown 
to be important for progression through the G1 phase, where 
cyclin E is expressed in late G1 that plays an important role in 
the G1 to S transition [42-45]. The increased protein expres-
sion of G1 cyclins in cancer cells has also been shown to be 
a major factor in driving uncontrolled growth because can-
cer cells either lack (with undetectable expression) CDKIs 
or they are non-functional [46]. The increased expression of 
CDKIs with decreased expression of cyclins and CDKs and 
decreased CDK kinase activity induced by PESV treatment 
in human prostate cancer cells suggest that PESV might be 
effective for the treatment or prevention of prostate cancer.
Apoptosis is regulated by several protein families, in-
cluding the upstream Bcl-2 family (e.g., the antiapoptotic 
Bcl-2 and proapoptotic Bax) and the downstream caspase 
family (e.g., caspase-3). The activation of apoptosis is con-
trolled at multiple checkpoints within the cell. Bcl-2 family 
Figure 4. Representative DNA histograms and percentage of cells in 
different cell cycle phases after incubated with 40mg/L of PESV (B) 
for 48 h in human DU145 cells by flow cytometry. The growing cells 
(60% confluent) were treated with PESV (40mg/L) for 48 hours, and 
the DNA cell cycle analysis was done as described in Materials and 
Methods. Columns, mean of three separate experiments conducted 
in triplicate with DU145 cells; bars, SE.
Figure 5. Representative image of cell cycle-related protein expres-
sion. P27kip1 (5a, 5b) and Cyclin E (5c, 5d). p27 expressed in the 
nuclei in DU145 cells treated with PESV (5b) is stonger than the 
control (5a); But Cyclin E expressed in the nuclei in DU145 cells 
treated with PESV (5d) is weaker than the control (5c).
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members are important regulators of apoptosis that include 
antiapoptotic (Bcl-2, Bcl-XL and Mcl-1), proapoptotic (Bax 
and  Bak)  and  the  BH3-domain-only  (Bim,  Bid  and  Bik) 
proteins [47]. Molecules belonging to the B-cell lympho-
ma leukaemia-2 (Bcl-2)/Bax system play a crucial role in 
the regulation of the apoptotic process. In particular, Bcl-2 
is an intracellular protein that inhibits apoptosis while Bax 
counteracts  the  anti-apoptotic  function  of  Bcl-2  by  bind-
ing to this molecule [36]. Upstream, the proapoptotic Bax 
and antiapoptotic Bcl-2 are membrane-bound pore-forming 
proteins that interact through heterodimerization. Together, 
they regulate the mitochondrial transmembrane passage of 
cytochrome C, which in turn activates caspase proteins. The 
Bax/Bcl-2 ratio appears more important than the individual 
Bax or Bcl-2 level in determining a cell’s vulnerability to 
apoptosis; high Bax/Bcl-2 ratios lead to greater apoptotic 
activity [36]. This study has also shown that PESV induces 
cell apoptosis in DU145 prostate cancer cells. We conformed 
that the induction of apoptosis was mediated through Bax 
overexpression with bcl-2 down regulation. 
Cancer develops when the balance between cell pro-
liferation and cell death is disturbed, and the aberrant cell 
proliferation leads to tumor growth. It is well known that 
apoptosis and its related signaling pathways have a profound 
effect on the progression of cancer [48-49], suggesting that 
agents inducing apoptotic death of human cancer cells may 
play a critical role in cancer prevention/intervention includ-
ing prostate cancer. In this regard, whereas there are several 
classes of chemotherapy drugs causing apoptotic death of 
cancer cells, their non-selective efficacy (toxicity) in other 
tissues has been a limitation in their efficacy. Our data dem-
onstrate significant apoptotic death induction by PESV only 
in prostate cancers, but not in normal prostate epithelial cells, 
suggesting the possibility of both selectivity and specificity 
in PESV efficacy against prostate cancer cells. 
More studies, however, are needed in the future to sup-
port this assumption, and to identify its mechanism of action 
in modulating mitogenic and survival signaling cascades in 
human prostate cancer. In addition, the significance of the 
observations made in the present study need to be estab-
lished in a broader context by conducting further studies in a 
variety of cell lines and xenograft animal models of human 
prostate cancer. The encouraging data suggest that PESV 
might be a promising agent in adjuvant therapy for prostate 
cancer. 
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